Terri Parker, MD
Assistant Professor of Medicine (Hematology)Cards
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Assistant Medical Director, Smilow Cancer Hospital, North Haven
Contact Info
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Assistant Medical Director, Smilow Cancer Hospital, North Haven
Contact Info
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Assistant Medical Director, Smilow Cancer Hospital, North Haven
Contact Info
About
Titles
Assistant Professor of Medicine (Hematology)
Assistant Medical Director, Smilow Cancer Hospital, North Haven
Biography
Terri Parker, MD, is an Assistant Professor of Medicine at the Yale School of Medicine in the section of Hematology. Dr. Parker completed her internal medicine residency at the University of Connecticut followed by a fellowship program in hospice and palliative medicine. She also completed a fellowship in hematology and medical oncology at Yale University School of Medicine.
Dr. Parker serves as the assistant medical director at Smilow Cancer Hospital in North Haven. She is a member of the protocol review committee (PRC) at Yale Cancer Center, which is charged with the scientific evaluation of all cancer clinical protocols and amendments proposed at Yale prior to initiation. Dr. Parker currently serves as co-chair of the Multiple Myeloma Committee for ClinicalPath, which presents evidence-based oncology pathways to academic and community practices.
Dr. Parker treats patients with plasma cell dyscrasias, including multiple myeloma and related diseases such as AL amyloidosis, monoclonal gammopathy of undetermined significance (MGUS), plasma cell leukemia, smoldering multiple myeloma, and Waldenstrom’s macroglobulinemia. She has experience with clinical trials focused on novel therapies and drug combinations with a goal of advancing the standard of care for patients with AL amyloidosis, newly diagnosed and relapsed refractory multiple myeloma.
Appointments
Hematology
Assistant ProfessorPrimary
Other Departments & Organizations
- Developmental Therapeutics
- Hematology
- Internal Medicine
- Leukemia & Lymphoma Program
- Multiple Myeloma and Gammopathies Program
- Yale Cancer Center
- Yale Medicine
- Yale Ventures
Education & Training
- Fellowship
- Yale University School of Medicine (2012)
- Fellowship
- University of Connecticut Health Center (2009)
- Residency
- University of Connecticut Health Center (2008)
- MD
- St. George's University School of Medicine Grenada (2005)
- BS
- University of Pittsburgh (2001)
Research
Overview
Medical Research Interests
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Natalia Neparidze, MD
Noffar Bar, MD
Stuart Seropian, MD
Sabrina Browning, MD
Elan Gorshein, DO, JD, MPH
Francine Foss, MD
Multiple Myeloma
Publications
2024
The Association between Glucagon-like Peptide-1 Receptor Agonist and Major Adverse Cardiac and Cerebrovascular Events in Monoclonal Gammopathy of Undetermined Significance: A Propensity-Score Analysis
Song J, Deshpande S, Chang Y, Chiang C, Ahn J, Lessa A, Soni A, Gonzales A, Lee P, Chang Y, Parker T, Kwan J, Chi K, Nanna M. The Association between Glucagon-like Peptide-1 Receptor Agonist and Major Adverse Cardiac and Cerebrovascular Events in Monoclonal Gammopathy of Undetermined Significance: A Propensity-Score Analysis. Blood 2024, 144: 6869. DOI: 10.1182/blood-2024-194867.Peer-Reviewed Original ResearchReal-World Efficacy and Patient-Reported Quality of Life Outcomes with Daratumumab Regimens in Multiple Myeloma
Browning S, Li F, Theprungsirikul P, Parker T, Bar N, Giri S, Anderson T, Stevens E, Gorshein E, Sabbath K, Wei C, Ali S, Witt D, Persico J, Talsania A, Rahmat L, Kidwai W, Legare R, LaSala J, Austin M, Neparidze N. Real-World Efficacy and Patient-Reported Quality of Life Outcomes with Daratumumab Regimens in Multiple Myeloma. Blood 2024, 144: 7831. DOI: 10.1182/blood-2024-204150.Peer-Reviewed Original ResearchConceptsRelapsed/refractory multiple myelomaInternational Myeloma Working GroupAdverse eventsGlobal health statusFunctional scalesMultiple symptom scalesPartial responseProteasome inhibitorsMultiple myelomaHealth statusEastern Cooperative Oncology Group performance statusClinical trialsMonoclonal antibody targeting CD38Median progression free survivalRelapsed/refractory multiple myeloma patientsIntroduction of novel therapiesHealth-related quality of lifeClinical response assessmentDaratumumab-based regimensProgression free survivalInfusion-related reactionsLines of therapyPatient-reported quality of life outcomesMean fatigue scoreHealth-related qualityA Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (DARA-VCD) Induction Followed By Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis
Hagen P, Sidana S, Parker T, Walker B, Sanchorawala V, Zonder J, Kourelis T, D'Souza A, Landau H, Rosenthal A, Hoering A, Ailawadhi S, Orlowski R. A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (DARA-VCD) Induction Followed By Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis. Blood 2024, 144: 3309.1-3309.1. DOI: 10.1182/blood-2024-208227.Peer-Reviewed Original ResearchConceptsAutologous stem cell transplantationNext generation flow cytometryStem cell transplantationOverall survivalConsolidation therapyAL amyloidCell transplantationASCT armLight chain (AL) amyloidosisSeverity of cardiac involvementFlow cytometryAL amyloid patientsDaratumumab to bortezomibTransplant related mortalityProgression free survivalHematologic response rateTwo-sided significance levelPlasma cell malignancyMulti-organ involvementDaratumumab maintenanceInduction therapyMRD negativityFree survivalIntergroup trialCardiac involvementIsatuximab in Relapsed AL Amyloidosis: Results of a Prospective Phase II Trial (SWOG S1702)
Parker T, Rosenthal A, Sanchorawala V, Landau H, Campagnaro E, Kapoor P, Neparidze N, Girnius S, Hagen P, Scott E, Hoering A, Durie B, Orlowski R. Isatuximab in Relapsed AL Amyloidosis: Results of a Prospective Phase II Trial (SWOG S1702). Blood 2024, 144: 3378-3378. DOI: 10.1182/blood-2024-208341.Peer-Reviewed Original ResearchConceptsMedian time to responseRelapsed AL amyloidosisTime to responseAL amyloidosisPartial responseHematologic responseComplete responseCardiac involvementOverall survivalRenal involvementOrgan involvementEastern Cooperative Oncology Group performance statusRate of hematologic responseAutologous stem cell transplantationProspective phase II trialLight chain (AL) amyloidosisDistribution of organ involvementProgression free survivalHematologic complete responseHematologic response rateStem cell transplantationPhase II trialAnti-CD38 antibodiesSystemic AL amyloidosisRate of patientsP-088 Evaluating T-cell Fitness Pre B-Cell Maturation Antigen (BCMA)-Targeted T-Cell Redirection Therapies (TRT) as a Predictive Marker for Efficacy/Toxicity in Relapsed/Refractory Multiple Myeloma (RRMM)
Theprungsirikul P, Yu M, Liu Y, Rall K, Matthews M, Neparidze N, Parker T, Browning S, Anderson T, Stevens E, Foss F, Gowda L, Pillai M, Isufi I, Seropian S, Mirza S, Bar N. P-088 Evaluating T-cell Fitness Pre B-Cell Maturation Antigen (BCMA)-Targeted T-Cell Redirection Therapies (TRT) as a Predictive Marker for Efficacy/Toxicity in Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia 2024, 24: s92-s93. DOI: 10.1016/s2152-2650(24)01991-8.Peer-Reviewed Original ResearchPrevalence of metabolic comorbidities and viral co-infections in monoclonal gammopathy: a retrospective analysis
Muradashvili T, Yu M, Browning S, Bar N, Gorshein E, Parker T, Neparidze N. Prevalence of metabolic comorbidities and viral co-infections in monoclonal gammopathy: a retrospective analysis. Leukemia 2024, 38: 2281-2283. PMID: 39164408, DOI: 10.1038/s41375-024-02380-x.Peer-Reviewed Original ResearchAltmetricAssociations of T-cell fitness prior to B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM).
Theprungsirikul P, Yu M, Rall K, Matthews M, Neparidze N, Parker T, Browning S, Anderson T, Stevens E, Foss F, Gowda L, Pillai M, Isufi I, Seropian S, Mirza S, Bar N. Associations of T-cell fitness prior to B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM). Journal Of Clinical Oncology 2024, 42: 7549-7549. DOI: 10.1200/jco.2024.42.16_suppl.7549.Peer-Reviewed Original ResearchCitationsConceptsChimeric antigen receptor T cellsRelapsed/refractory multiple myelomaT cell fitnessHigh-risk cytogeneticsCytokine release syndromeNon-respondersExtramedullary diseaseT cellsPeripheral blood prior to treatmentInternational Myeloma Working Group criteriaNR groupBlood prior to treatmentBispecific T-cell engagerMedian follow-up timeMedian prior linesT-cell therapyPost-treatment follow-upT-cell engagersT cell influxT-cell %Working Group criteriaYale Cancer CenterMann-Whitney U testResponse to disease progressionIdecabtagene vicleucelA phase III, randomized study of daratumumab, cyclophosphamide, bortezomib and dexamethasone (DARA-VCD) induction followed by autologous stem cell transplant or DARA-VCD consolidation and daratumumab maintenance in patients with newly diagnosed AL amyloidosis.
Hagen P, Sidana S, Parker T, Walker B, Hoering A, Sanchorawala V, Zonder J, Kourelis T, D'Souza A, Landau H, Rosenthal A, Ailawadhi S, Orlowski R. A phase III, randomized study of daratumumab, cyclophosphamide, bortezomib and dexamethasone (DARA-VCD) induction followed by autologous stem cell transplant or DARA-VCD consolidation and daratumumab maintenance in patients with newly diagnosed AL amyloidosis. Journal Of Clinical Oncology 2024, 42: tps7575-tps7575. DOI: 10.1200/jco.2024.42.16_suppl.tps7575.Peer-Reviewed Original ResearchConceptsAutologous stem cell transplantationProgression free survivalStem cell transplantationOverall survivalCell transplantationASCT armNext generation flow cytometryLight chain (AL) amyloidosisDaratumumab to bortezomibDiagnosed AL amyloidosisTwo-sided significance levelPlasma cell malignancyShort follow-upDaratumumab maintenanceMRD negativityFree survivalInduction therapyIntergroup trialMultiple myelomaAL amyloidosisHematologic responseRenal responseRandomized studyCell malignancyFollow-upA Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (DARA-VCD) Induction Followed by Autologous Stem Cell Transplant or DARA-VCD Consolidation and Daratumumab Maintenance in patients with Newly Diagnosed AL Amyloidosis PA145 (#114)
Hagen P, Hoering A, Sidana S, Parker T, Walker B, Sanchorawala V, Zonder J, Kourelis T, D’Souza A, Landau H, Rosenthal A, Ailawadhi S, Z. R. A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (DARA-VCD) Induction Followed by Autologous Stem Cell Transplant or DARA-VCD Consolidation and Daratumumab Maintenance in patients with Newly Diagnosed AL Amyloidosis PA145 (#114). 2024 DOI: 10.26226/m.65f9bf89e6f73964e1d4eb32.Peer-Reviewed Original Research
2021
Outcomes Among Primary Refractory Multiple Myeloma Patients in the Era of Monoclonal Antibodies: The Yale Experience
Liu Y, Kywe B, Crawford L, Lora F, Bar N, Browning S, Gorshein E, Parker T, Neparidze N. Outcomes Among Primary Refractory Multiple Myeloma Patients in the Era of Monoclonal Antibodies: The Yale Experience. Blood 2021, 138: 1635. DOI: 10.1182/blood-2021-146619.Peer-Reviewed Original ResearchCitationsConceptsAutologous stem cell transplantMedian overall survivalInternational Staging System stage IIRefractory multiple myeloma patientsOverall survivalMultiple myeloma patientsMultiple myelomaInduction therapyPartial responsePrimary refractoryInduction regimenMyeloma patientsMonoclonal antibodiesPlasma cellsInternational Myeloma Working Group criteriaYale New Haven Health SystemStage IIHigh-risk cytogeneticsGood partial responseRetrospective cohort studyMajority of patientsMRD-negative statusMonoclonal antibody therapyStem cell transplantImportant prognostic value
Clinical Trials
Current Trials
A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM)
HIC ID2000033033RolePrincipal InvestigatorPrimary Completion Date06/18/2027Recruiting ParticipantsNovel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
HIC ID2000028918RoleSub InvestigatorPrimary Completion Date01/01/2025Recruiting ParticipantsEffective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation
HIC ID2000029969RoleSub InvestigatorPrimary Completion Date12/31/2027Recruiting ParticipantsA Prospective, Observational Study of Real-World Efficacy and Patient-Reported Quality of Life
HIC ID2000026739RoleSub InvestigatorPrimary Completion Date07/01/2021Recruiting ParticipantsDaratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
HIC ID2000025737RoleSub InvestigatorPrimary Completion Date12/31/2029Recruiting Participants
Academic Achievements & Community Involvement
activity Protocol Review Committee, Yale Cancer Center, Yale University School of Medicine
CommitteesCommittee MemberDetailsMember of the scientific protocol review committee for the cancer center. The committee is responsible for reviewing the scientific merit, priorities, and progress of Yale Cancer Center clinical research trials.2015 - Presentactivity American Society of Hematology
Professional OrganizationsVolunteerDetailsChosen as an inaugural American Society of Hematology (ASH) Ambassador. This was a formal volunteer role to support recruitment and retention of trainees to hematology and to ASH through promotion of ASH’s career development and training programs.2018 - 2021activity Faculty Advisory Council, Yale University School of Medicine
CommitteesCommittee MemberDetailsThe purpose of the Faculty Advisor Council is to provide a forum for a diverse group of representatives to bring new ideas and concerns from a broad range of faculty to the Dean’s office. I served a two year term representing the sections of hematology/medical oncology.2015 - 2017honor David S. Fischer Teaching Award for Outstanding Faculty Teaching and Mentoring of Fellows in Medical Oncology
Yale School of Medicine AwardDetails06/08/2016United Stateshonor Letter of Recognition from Evaluation and Promotions Committee
Other AwardUniversity of ConnecticutDetails12/01/2006United States
Clinical Care
Overview
Terri Parker, MD, is a hematologist and assistant medical director at the Smilow Cancer Hospital Care Center in North Haven.
Dr. Parker treats patients with plasma cell dyscrasias, including multiple myeloma, and related diseases such as AL amyloidosis, monoclonal gammopathy of undetermined significance (MGUS), plasma cell leukemia, smoldering multiple myeloma, and Waldenstrom’s macroglobulinemia.
“These are all disorders where the primary abnormality is in the plasma cell. Plasma cells are a type of white blood cell,” Dr. Parker explains. “I was drawn to hematology because it isn’t just one organ system involved. It touches on everything. And I love the continuity of care it provides as I get to know my patients.”
Dr. Parker says she is encouraged by the advances that have been made in recent years in terms of new therapies for conditions like multiple myeloma. “Right now, there isn’t a cure for multiple myeloma, but it’s very treatable,” she says.
She says she also enjoys the team aspect of her job. “It isn’t just me a patient sees but there is a whole team caring for the patient including advanced practice providers such as physician’s assistants, other myeloma specialists, a dedicated pharmacist, social worker, and a nutritionist. There is also a support group for patients,” she says.
Dr. Parker’s research interests focus on novel therapies and drug combinations to improve care for patients with AL amyloidosis, newly diagnosed and relapsed refractory multiple myeloma.
Clinical Specialties
Fact Sheets
Multiple Myeloma
Learn More on Yale MedicineDiagnosing Leukemia
Learn More on Yale MedicineCytogenic Studies for Leukemia Diagnosis
Learn More on Yale MedicineLeukemia in Children
Learn More on Yale Medicine
Board Certifications
Medical Oncology
- Certification Organization
- AB of Internal Medicine
- Latest Certification Date
- 2015
- Original Certification Date
- 2013
Hematology (Internal Medicine)
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2012
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews & Links
News
- December 18, 2024
Yale research advances presented at American Society of Hematology annual meeting
- March 25, 2024
Yale’s Post ASH Review
- September 14, 2023
Smilow Shares: AL Amyloidosis
- June 28, 2021
Meet Dr. Terri Parker
Get In Touch
Contacts
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.